Fresenius SE & Co. KGaA (FSNUF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FSNUF representa a Fresenius SE & Co. KGaA, una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Fresenius SE & Co. KGaA (FSNUF) Resumen de Asistencia Médica y Tuberías
Fresenius SE & Co. KGaA, a German-based healthcare conglomerate with a $30.61 billion market cap, delivers dialysis products, hospital management, and outpatient care services. Operating across four segments, Fresenius balances established healthcare solutions with expansion into biosimilars and fertility treatments, maintaining a 5.1% profit margin in a competitive global market.
Tesis de Inversión
Fresenius presents a mixed investment case. The company's diversified healthcare segments offer stability, with Fresenius Medical Care providing a consistent revenue stream. The expansion into biosimilars through Fresenius Kabi represents a growth opportunity, targeting a market projected to reach $100 billion by 2025. Fresenius Helios' hospital network in Germany and Spain provides a stable base for healthcare service delivery. However, the company's 22.98 P/E ratio reflects market expectations, and a 2.14% dividend yield offers moderate income. Investors should monitor the performance of Fresenius Kabi's biosimilar pipeline and the impact of healthcare regulations on Fresenius Helios' operations. Key risks include currency fluctuations and potential changes in reimbursement policies.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $30.61 billion, reflecting its significant presence in the healthcare sector.
- P/E ratio of 22.98, indicating investor expectations for future earnings growth.
- Profit margin of 5.1%, demonstrating the company's ability to generate profit from its revenue.
- Gross margin of 25.0%, reflecting the efficiency of its production and service delivery.
- Dividend yield of 2.14%, providing a steady income stream for investors.
Competidores y Pares
Fortalezas
- Diversified business model across multiple healthcare segments.
- Global presence with operations in over 100 countries.
- Established market position in dialysis products and services.
- Strong brand reputation and long-standing relationships with healthcare providers.
Debilidades
- Exposure to regulatory changes and reimbursement pressures.
- Dependence on Fresenius Medical Care for a significant portion of revenue.
- Currency fluctuations can impact financial performance.
- Competition from other healthcare providers and pharmaceutical companies.
Catalizadores
- Ongoing: Expansion of Fresenius Kabi's biosimilars portfolio, targeting a market projected to reach $100 billion by 2025.
- Ongoing: Increasing demand for dialysis services due to the rising prevalence of chronic kidney disease.
- Upcoming: Potential strategic acquisitions to expand product portfolio and geographic reach.
- Ongoing: Development and implementation of digital health solutions to improve patient care and operational efficiency.
Riesgos
- Ongoing: Exposure to regulatory changes and reimbursement pressures in the healthcare industry.
- Ongoing: Dependence on Fresenius Medical Care for a significant portion of revenue.
- Potential: Currency fluctuations can impact financial performance.
- Potential: Economic downturns can impact healthcare spending.
- Potential: Product liability claims and litigation risks.
Oportunidades de crecimiento
- Expansion of Biosimilars Portfolio: Fresenius Kabi's biosimilars business represents a significant growth opportunity. The global biosimilars market is projected to reach $100 billion by 2025, driven by the expiration of patents for blockbuster biologic drugs. Fresenius Kabi's pipeline of biosimilars targets autoimmune and oncology diseases, offering potential for increased revenue and market share. Success in this area depends on navigating regulatory approvals and competing with established pharmaceutical companies.
- Growth in Emerging Markets: Fresenius has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical services is increasing. These markets offer potential for higher growth rates compared to developed countries. Fresenius can leverage its expertise in dialysis, hospital management, and pharmaceutical products to establish a foothold in these regions. However, navigating regulatory environments and cultural differences will be crucial for success.
- Increased Demand for Dialysis Services: The prevalence of chronic kidney disease is increasing globally, driving demand for dialysis services. Fresenius Medical Care, as a leading provider of dialysis products and services, is well-positioned to benefit from this trend. The company can expand its dialysis center network and develop innovative dialysis technologies to meet the growing demand. Factors such as aging populations and the rise of diabetes contribute to the increasing need for dialysis.
- Strategic Acquisitions: Fresenius can pursue strategic acquisitions to expand its product portfolio, geographic reach, and market share. Acquisitions can provide access to new technologies, therapeutic areas, and customer segments. Fresenius has a history of successful acquisitions, and it can leverage its financial resources and expertise to identify and integrate complementary businesses. However, careful due diligence and integration planning are essential to ensure the success of acquisitions.
- Digital Health Solutions: Fresenius can leverage digital health technologies to improve patient care, enhance operational efficiency, and develop new revenue streams. Digital health solutions include telehealth, remote monitoring, and data analytics. These technologies can improve access to care, reduce costs, and personalize treatment. Fresenius can partner with technology companies and invest in research and development to develop innovative digital health solutions. However, data privacy and security concerns must be addressed.
Oportunidades
- Expansion of biosimilars portfolio through Fresenius Kabi.
- Growth in emerging markets with increasing demand for healthcare services.
- Increased demand for dialysis services due to rising prevalence of chronic kidney disease.
- Strategic acquisitions to expand product portfolio and geographic reach.
Amenazas
- Economic downturns can impact healthcare spending.
- Changes in government regulations and healthcare policies.
- Technological advancements can disrupt existing business models.
- Product liability claims and litigation risks.
Ventajas competitivas
- Established market position in dialysis products and services through Fresenius Medical Care.
- Diversified business model across multiple healthcare segments.
- Global presence with operations in over 100 countries.
- Strong brand reputation and long-standing relationships with healthcare providers.
Acerca de FSNUF
Founded in 1912 and headquartered in Bad Homburg vor der Höhe, Germany, Fresenius SE & Co. KGaA has evolved into a global healthcare provider. Initially focused on pharmaceutical preparations, the company expanded into dialysis in the 1960s, marking a pivotal shift. Today, Fresenius operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care, the largest segment, provides products and services for individuals with chronic kidney failure, including dialyzers, machines, and related services. Fresenius Kabi focuses on therapies for critically and chronically ill patients, offering IV drugs, nutrition products, infusion solutions, biosimilars, and medical devices. Fresenius Helios operates hospitals and outpatient clinics in Germany and Spain, providing comprehensive medical care. Fresenius Vamed manages projects and offers services for healthcare facilities, including project development, construction, and operational management. With a global presence spanning over 100 countries and approximately 175,202 employees, Fresenius is a significant player in the healthcare industry, balancing product manufacturing with healthcare service delivery.
Qué hacen
- Provides products and services for dialysis patients.
- Manages hospitals and outpatient clinics.
- Offers intravenous drugs and clinical nutrition products.
- Develops and manages healthcare projects.
- Manufactures dialyzers and hemodialysis machines.
- Provides services in the field of fertility treatments.
- Offers biosimilars for autoimmune and oncology diseases.
Modelo de Negocio
- Provides dialysis products and services to patients with chronic kidney failure.
- Operates hospitals and outpatient clinics, generating revenue from patient care services.
- Develops and sells intravenous drugs, clinical nutrition products, and biosimilars.
- Manages healthcare projects, providing project development, construction, and operational management services.
Contexto de la Industria
Fresenius operates in the healthcare industry, which is characterized by increasing demand due to an aging global population and advancements in medical technology. The industry is subject to stringent regulations and reimbursement policies, impacting profitability. The competitive landscape includes major players like BAYRY and FMCQF, as well as specialized companies in dialysis, pharmaceuticals, and hospital management. Fresenius' diversified business model allows it to capture revenue across multiple healthcare segments, mitigating risks associated with specific areas. The global healthcare market is projected to reach $10 trillion by 2022, presenting opportunities for growth and expansion.
Clientes Clave
- Patients with chronic kidney failure requiring dialysis treatment.
- Hospitals and healthcare facilities seeking management and operational services.
- Critically and chronically ill patients requiring intravenous drugs and clinical nutrition.
- Patients seeking treatment at Fresenius Helios hospitals and outpatient clinics.
Finanzas
Gráfico e información
Precio de la acción de Fresenius SE & Co. KGaA (FSNUF): Price data unavailable
Últimas noticias
-
Here's Why Fresenius (FMS) is a Strong Value Stock
Zacks · 9 feb 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para FSNUF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para FSNUF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de FSNUF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Michael Sen
CEO
Michael Sen brings extensive leadership experience to Fresenius SE & Co. KGaA. Before joining Fresenius, he held key executive positions at Siemens, including serving as a member of the managing board. His background spans various industries, including energy, healthcare, and industrial automation. Sen's expertise lies in strategic planning, operational excellence, and business transformation. He holds advanced degrees in engineering and business administration.
Historial: Since assuming the role of CEO, Michael Sen has focused on streamlining operations, driving innovation, and expanding Fresenius' global reach. He has overseen strategic acquisitions and partnerships to strengthen the company's position in key markets. Sen has also emphasized sustainability and corporate social responsibility, aligning Fresenius' business practices with environmental and social goals. His leadership has been instrumental in navigating the challenges of the healthcare industry and positioning Fresenius for long-term growth.
Información del mercado OTC de FSNUF
The OTC Other tier represents the lowest tier of over-the-counter (OTC) securities. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often have limited regulatory oversight and reporting requirements. Companies in this tier may not meet minimum financial standards or may be unwilling to comply with stricter listing requirements. This tier is generally associated with higher risk due to the potential for fraud, lack of transparency, and limited liquidity compared to exchange-listed securities.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of fraud or manipulation.
- Limited financial disclosure makes it difficult to assess the company's financial health.
- Price volatility can be higher due to lower trading volume.
- Potential for delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Obtain and review audited financial statements.
- Assess the company's management team and track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Understand the OTC market and its associated risks.
- Consult with a financial advisor before investing.
- The company has been in operation for over a century, indicating a degree of stability.
- Fresenius has a global presence and operates in multiple healthcare segments.
- The company has a market capitalization of over $30 billion, suggesting a significant scale of operations.
- Fresenius has a history of acquisitions and partnerships, demonstrating strategic growth initiatives.
FSNUF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar FSNUF?
Fresenius SE & Co. KGaA (FSNUF) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Diversified business model across multiple healthcare segments.. Riesgo principal a monitorear: Ongoing: Exposure to regulatory changes and reimbursement pressures in the healthcare industry.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de FSNUF?
FSNUF actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de FSNUF?
Los precios de FSNUF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre FSNUF?
La cobertura de analistas para FSNUF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en FSNUF?
Las categorías de riesgo para FSNUF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Exposure to regulatory changes and reimbursement pressures in the healthcare industry.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de FSNUF?
La relación P/E para FSNUF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está FSNUF sobrevalorada o infravalorada?
Determinar si Fresenius SE & Co. KGaA (FSNUF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de FSNUF?
Fresenius SE & Co. KGaA (FSNUF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- OTC market data may have limited reliability compared to major exchanges.
- AI analysis pending for FSNUF, further insights may be available in the future.